Table 3 The role of CAFs labeled by bidirectional function markers in various kinds of cancer
From: What is new in cancer-associated fibroblast biomarkers?
Bio marker | Main origin | Description | Roles in cancers | |||
|---|---|---|---|---|---|---|
Pancreatic cancer | Breast cancer | Colorectal cancer | Lung cancer | |||
Cav-1 | NFs | A scaffold protein | Higher CA19-9 level and rates of advanced tumor stage; lower DFS and OS | Cav-1 deficiency is associated with early recurrence, late tumor stage, lymph node metastasis, triamcinolone resistance and poor prognosis; Cav-1 upregulation hardening TME to promote tumor cell invasion and metastasis | Tumor-promoting | A marker of good efficacy for nab-paclitaxel treatment |
PDPN | Vascular endothelial cells | Mucin-type salivary glycoprotein | Associated with immune-related signatures and recruitment of dendritic cells; enhancing the progression, and serving as an independent predictor of poor outcome | Good independent prognostic marker | PNPDhigh CAFs are protective against cell invasion; associated with favorable clinicopathological parameters and prolonged DFS | PDPN+CAFs are related to immunosuppressive microenvironment; leading to primary resistance to EGFR-TKI by activating MAPK signaling; a risk factor for recurrence |
CD200 | Not clear | OX2 membrane glycoprotein | No clear correlation with PFS and OS | - | - | Increasing sensitivity of EGFR mutation lung cancer to the EGFR-TKI |